ANDA 210231, held by J Molner. Succinylcholine Chloride.
As of Nov 16, 2026, ANDA 210231 (Succinylcholine Chloride), held by J Molner, was first approved by FDA on Jun 4, 2018, with 3 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Succinylcholine chloride is indicated as an adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery or mechanical ventilation.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jun 4, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Succinylcholine Chloride20MG/ML · injectable;injection | Succinylcholine Chloride | Rx |
| Oct 15, 2020 | Supplement 4Labeling · Standard review | Approved | None posted |
| Feb 10, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| Feb 10, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| Jun 4, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters